Advertisement

Loading...

Virax Biolabs Group Limited

VRAX•NASDAQ
Healthcare
Biotechnology
$0.22
$0.06(35.32%)
U.S. Market opens in 0h 55m

Virax Biolabs Group Limited (VRAX) Stock Overview

Explore Virax Biolabs Group Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap954.8K
P/E Ratio-0.17
EPS (TTM)$-1.22
ROE-1.03%
Fundamental Analysis

AI Price Forecasts

1 Month$-0.17
3 Months$0.00
1 Year Target$0.00

VRAX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Virax Biolabs Group Limited (VRAX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.43, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.17 and a market capitalization of 954.8K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
35.32%
5-Day Change
17.59%
1-Month Change
-3.43%
3-Month Change
-36.41%
6-Month Change
-63.84%
Year-to-Date (YTD) Change
-42.73%
1-Year Change
-80.71%
3-Year Change
-96.84%
5-Year Change
-99.88%
All-Time (Max) Change
-99.88%

Contact Information

https://viraxbiolabs.com
44 20 7788 7414
30 Broadwick Street, London, NaN, W1F 8LX

Company Facts

170 Employees
IPO DateJul 21, 2022
CountryGB
Actively Trading

Frequently Asked Questions